Polimiositis y dermatomiositis refractaria en adultos: Opciones terapéuticas

Autores/as

Palabras clave:

Dermatomiositis, Polimiositis, Terapéutica, Acciones farmacológicas, Miositis

Resumen

La dermatomiositis y polimiositis son enfermedades autoinmunes raras, clasificadas dentro de las miopatías inflamatorias, y caracterizadas clínicamente por debilidad muscular, frecuentemente acompañada de manifestaciones extramusculares. Los pacientes usualmente logran la remisión o niveles bajos de actividad de la enfermedad con el tratamiento inicial con glucocorticoides (pueden o no estar asociados a inmunomoduladores), cuando este falla se considera una dermatomiositis y polimiositis refractarias (antes se debe realizar una nueva biopsia muscular para descartar diagnósticos alternativos) por lo cual se requerirán tratamientos adicionales para su manejo. El tratamiento de la dermatomiositis y polimiositis refractarias continúa siendo un reto debido a la falta de evidencia científica que permita validar la efectividad de fármacos alternativos. Esta revisión presenta algunas de las alternativas terapéuticas. Se encontró en la literatura como prometedoras para disminuir la morbimortalidad en ambas patologías las terapias biológicas, especialmente el rituximab y abatacept.

Biografía del autor/a

María Camila Guerrero-Oviedo, Pontificia Universidad Javeriana Cali (Colombia)

Estudiante de Medicina, Semillero de Innovadores en Salud ISSEM.

Freddy Moreno-Gomez , Pontificia Universidad Javeriana Cali (Colombia)

Odontólogo, Magíster en Ciencias Biomédicas, Profesor Departamento de Ciencias Básicas de la Salud.

Citas

Amato AA, Greenberg SA. Inflammatory Myopathies. CONTINUUM: Lifelong Learning in Neurology. 2013; (6):1615-33. DOI: 10.1212/01.CON.0000440662.26427.bd

Atluri R. Inflammatory Myopathies. Mo med. 2016; 113(2):127-3.

Lundberg IE, Miller FW, Tjärnlund A, Bottai M. Diagnosis and classification of idiopathic inflammatory myopathies. Journal of Internal Medicine. 2016; (1):39-51. DOI: 10.1111/joim.12524

Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, GrauJunyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. The Lancet Neurology. 2018; (9):816-28. DOI: 10.1016/S1474-4422(18)30254-0

Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, et al. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurology. 2018; (12):1528. DOI: 10.1001/jamaneurol.2018.2598

Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyo-itis. Muscle & Nerve. 2015; (5):638-56. DOI: 10.1002/mus.24566

Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Modern Rheumatology. 2018; (1):1-19. DOI: 10.1080/14397595.2018.1521185

Keyßer G, Zierz S, Kornhuber M. Treatment of adult idiopathic inflammatory myopathies with conventional immunosuppressive drugs. Zeitschrift für Rheumatologie. 2018; (2):183-9. DOI: 10.1007/s00393-018-0471-0

Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Research & Therapy. 2012; 1: R22. DOI: 10.1186/ar3704

Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and im-munomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database of Systematic Reviews. 2012. DOI: 10.1002/14651858.CD003643.pub4

Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyo-sitis. Annals of the Rheumatic Diseases. 2017; (5):792-801. DOI: 10.1136/annrheumdis-2017-211400

Miller M, MD. Treatment of recurrent and resistant dermatomyositis and polymyositis in adults. Uptodate. 2021. Disponible en: https://n9.cl/48blz

Ibrahim F, Choy E, Gordon P, Doré CJ, Hakim A, Kitas G, et al. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rheumatology. 2014; (6):1050-5. DOI: 10.1093/rheumatology/keu442

Antonio CC, Juan RG. Tratado de medicina intensiva + acceso web (Spanish Edi-tion). Barcelona: Elsevier España, S.L.U.; 2017.

Matsubara S, Kondo K, Sugaya K, Miyamoto K. Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature. Clinical Rheumatology. 2012; (10):1493-8. DOI: 10.1007/s10067-012-2044-y

Rotella K, Alvarez MR, Saperstein Y, Bhamra MS, Leon SZ, Feoktistov A et al. Tacrolimus Induced Remission in Drug Resistant Inflammatory Myopathy: A Case Series. Rheumatology: Current Research. 2018; (02). DOI: 10.4172/2161-1149.1000238

Quick A, Tandan R. Mechanisms of Action of Intravenous Immunoglobulin in Inflammatory Muscle Disease. Current Rheumatology Reports. 2011; (3):192-8. DOI: 10.1007/s11926-011-0171-0

Patwardhan A. The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics. Cureus. 2020; (2): 19;12. DOI: 10.7759/cureus.7049

Galimberti F, Kooistra L, Li Y, Chatterjee S, Fernandez AP. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis. Clinical and Experimental Dermatology. 2018; (8):906-12. DOI: 10.1111/ced.13607

Foreman C, Russo P, Davies N, Hissaria P, Proudman S, Hughes T et al. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients. Internal Medicine Journal. 2017; (1):112-5. DOI: 10.1111/imj.13308

Kampylafka EI, Kosmidis ML, Panagiotakos DB, Dalakas M, Moutsopoulos HM, Tzioufaz AG. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study. Clinical and experimental rheumatology. 2012; 30(3):397-401.

Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis re-sistant to corticosteroids: a randomized double-blind placebo-controlled trial. Modern Rheumatology. 2012; 3:382-93. DOI: 10.3109/s10165-011-0534-4

Walkiewicz-Pielaszek K, Swacha M, Bułło-Piontecka B, Rutkowski B, Olesiñska M. Mycophenolate mofetil-20 years of experience in treatment of rheumatic diseases. 2015; 6;69:176-87.

Olivo Pallo PA, de Souza FHC, Miossi R, Shinjo SK. Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series. Advances in Rheumatology. 2018; 1. DOI: 10.1186/s42358-018-0035-7

Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy. Clinical Rheumatology. 2018; (2):585-90. DOI: 10.1007/s10067-018-4294-9

Robert RM, Thomas FMFF, William SMP, Anthony FMF, Cornelia WMP. Clinical Immunology: Principles and Practice. Fifth edition. Elsevier; 2019.

Nagappa M, Taly AB, Sinha S, Gayathri N, Bindu PS, Mahadevan A, et al. Efficacy and Limitations of Pulse Cyclophosphamide Therapy in Polymyositis and Dermatomyositis. Journal of Clinical Neuromuscular Disease. 2013; 4:161-8. DOI: 10.1097/CND.0b013e31828ee91

Bae S, Charles-Schoeman C. Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study. Clini-cal Rheumatology. 2018; (8):2113-23. DOI: 10.1007/s10067-018-4174-3

Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN. Cyclophosphamide for connective tissue disease associated interstitial lung disease. Cochrane Database of Systematic Reviews. 2018. DOI: 10.1002/14651858.CD010908.pub2

Ge Y, Peng Q, Zhang S, Zhou H, Lu X, Wang G. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clinical Rheumatology. 2014; (1):99-105. DOI: 10.1007/s10067-014-2803-z

Gary FM, Ralph BM, Sherine GMMs, Iain MPFFFm, James OM. Kelley and Firestein’s Textbook of Rheumatology. Tenth Edition. Elsevier; 2017.

Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo phase trial. Arthritis & Rheumatism. 2013; (2):314-24. DOI: 10.1002/art.37754

Muñoz-Beamud F, Isenberg DA. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2013; (6)31:896-903.

Aggarwal R. Rituximab in myositis. Rheumatology. 2011; (12):2155-6. Disponible en: DOI: 10.1093/rheumatology/ker138

Sánchez-Fernández SÁ, Carrasco Fernández JA, Rojas Vargas LM. Eficacia de ritu-ximab en dermatomiositis y polimiositis refractarias al tratamiento convencional. Reumatología Clínica. 2013; (2):117-9. DOI: 10.1016/j.reuma.2012.02.007

Abdul Halim S, Mohd Yusoff S. Refractory polymyositis with prolonged respiratory failure successfully treated with rituximab therapy. Journal of the Neurological Sciences. 2017; 263-4. DOI: 10.1016/j.jns.2017.08.751

Innami K, Mukai T, Kodama S, Morita Y. Successful treatment using rituximab in a patient with refractory polymyositis complicated by scleroderma renal crisis. BMJ Case Reports [Internet]. 2017; bcr-2017-221205. Disponible en: http://dx.doi.org/10.1136/bcr-2017-221205

Gheita TA, Gheita HA, Kenawy SA. Rituximab restored the muscle power and rescued from a refractory fatal respiratory failure in a patient with elderly onset polymyositis. Joint Bone Spine. 2012; (1):101-2. DOI: 10.1016/j.jbspin.2011.06.006

Wesley BM A, Stephen HMDF, Robyn OM, Leonard BM, David, Gurjit KHMP et al. Middleton’s Allergy: Principles and Practice (middletons Allergy Principles and Practice). Ninth edition. Elsevier; 2020.

Tjärnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasová Studýnková J, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed start trial. Annals of Rheumatic Diseases. 2017; (1):55-62. DOI: 10.1136/annrheumdis-2017-211751

Çağlayan M, Işik H, Oktayoglu P. A Case of Refractory Polymyositis Successfully Treated with Abatacept Monotherapy. Archives of Rheumatology. 2020; (4):618-22. DOI: 10.46497/ArchRheumatol.2020.7406

Kerola AM, Kauppi MJ. Abatacept as a successful therapy for myositis. A case-based review. Clinical Rheumatology. 2014; (3):609-12. DOI: 10.1007/s10067-014-2507-4

Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine. 2011; (4):431-2. DOI: 10.1016/j.jbspin.2011.03.022

Gary FM, Ralph BM, Sherine GMMs, Iain MPFFFm, James OM. Kelley and Firestein’s Textbook of Rheumatology. Tenth edition. Elsevier; 2018.

Aggarwal R, Rockette H, Venturupalli S, Marder G, Dimachkie M, Gazeley D, Ernste FC, Crofford L, Moghadam-Kia S, Koontz D, Zhu L, Oddis C. Tocilizumab in Myositis: Results of a Phase IIb Double-Blind Randomized Controlled Trial. Arthritis and Rheumatology. 2020; 72 (suplemento 10).

Infliximab: Uses, Interactions, Mechanism of Action. DrugBank Online. Database for Drug and Drug Target Info. Disponible en: https://go.drugbank.com/drugs/DB00065

Ge Y, Li S, Chen F, He L, Li C, Lu X, et al. The effects of infliximab in treating idio-pathic inflammatory myopathies: A review article. Dermatologic Therapy. 2021; e14976. DOI: 10.1111/dth.14976

Tofacitinib: Uses, Interactions, Mechanism of Action. DrugBank Online. Database for Drug and Drug Target Info. Disponible en: https://go.drugbank.com/drugs/DB08895

Moghadam-Kia S, Charlton D, Aggarwal R, Oddis CV. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology. 2019; (6):1011-5. DOI: 10.1093/rheumatology/key366

Paik JJ, Casciola-Rosen L, Shin JY, Albayda J, Tiniakou E, Leung DG, et al. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients. Arthritis & Rheumatology. 2021; (5):858-65. DOI: 10.1002/art.41602

Cozzi F, Marson P, Pigatto E, Tison T, Polito P, Galozzi P, et al. Plasma exchange as a “rescue therapy” for dermato/polymyositis in acute phase. Experience in three young patients. Transfusion and Apheresis Science. 2015; (3):368-72. DOI: 10.1016/j.transci.2015.07.005

Ning Y, Yang G, Sun Y, Chen S, Liu Y, Shi G. Efficiency of Therapeutic Plasma-Exchange in Acute Interstitial Lung Disease, Associated with Polymyositis/Dermatomyositis Resistant to Glucocorticoids and Immunosuppressive Drugs: A Retrospective Study. Frontiers in Medicine. 2019; (6):239 DOI: 10.3389/fmed.2019.00239

Abe Y, Kusaoi M, Tada K, Yamaji K, Tamura N. Successful treatment of anti-MDA5 antibody positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology. 2019; (4):767-71. DOI: 10.1093/rheumatology/kez357

Descargas

Publicado

2023-03-30

Cómo citar

Guerrero-Oviedo, M. C., & Moreno-Gomez , F. (2023). Polimiositis y dermatomiositis refractaria en adultos: Opciones terapéuticas. Salutem Scientia Spiritus, 9(1), 59–65. Recuperado a partir de https://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/1308

Número

Sección

Revisión de la literatura

Artículos más leídos del mismo autor/a

<< < 1 2 3 > >>